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Summary
Mounting evidence suggests that mitochondrial dysfunction plays a causal role in
the etiology and progression of Alzheimer’s disease (AD). We recently showed that
the carbonic anhydrase inhibitor (CAI) methazolamide (MTZ) prevents amyloid b
(Ab)-mediated onset of apoptosis in the mouse brain. In this study, we used MTZ
and, for the first time, the analog CAI acetazolamide (ATZ) in neuronal and cerebral
vascular cells challenged with Ab, to clarify their protective effects and mitochon-
drial molecular mechanism of action. The CAIs selectively inhibited mitochondrial
dysfunction pathways induced by Ab, without affecting metabolic function. ATZ
was effective at concentrations 10 times lower than MTZ. Both MTZ and ATZ pre-
vented mitochondrial membrane depolarization and H2O2 generation, with no
effects on intracellular pH or ATP production. Importantly, the drugs did not primar-
ily affect calcium homeostasis. This work suggests a new role for carbonic anhy-
drases (CAs) in the Ab-induced mitochondrial toxicity associated with AD and
cerebral amyloid angiopathy (CAA), and paves the way to AD clinical trials for CAIs,
FDA-approved drugs with a well-known profile of brain delivery.
K E YWORD S
Alzheimer’s disease, amyloid b, carbonic anhydrase inhibitors, acetazolamide, methazolamide,
mitochondria
1 | INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent type of dementia in
the developed world. Despite the enormous efforts made by the sci-
entific community, an effective therapeutic strategy against AD has
yet to be developed. The importance of mitochondrial dysfunction in
the pathogenesis of AD and other neurodegenerative diseases has
been increasingly recognized (Mancuso, Coppede, Murri & Siciliano,
2007; Swerdlow, Burns & Khan, 2010). A causal relationship has
been found between mitochondrial dysfunction and amyloid b (Ab)-
induced neuronal and vascular degeneration (Abramov, Scorziello &
Duchen, 2007; Fossati et al., 2010; Swerdlow et al., 2010). Indeed,
mitochondrial pathology, oxidative stress, and energy metabolism
impairment are implicated in the pathogenesis of AD and present in
patients with AD and transgenic animal models, preceding formation
of Ab plaques, cell death, and memory loss (Beal, 2005). Little atten-
tion has been paid to the mitochondrial molecular/biochemical path-
ways leading to AD. The scientific community emphasizes the need
to explore mitochondrial pathways to provide solutions to unan-
swered questions in the prevention and treatment of the disease.
Mitochondrial-specific therapies are emerging as promising thera-
peutic tools. It is interesting that mitochondrial therapies have
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shown beneficial effects in different models of neurodegenerative
pathologies, where mitochondrial dysfunction and apoptotic cell
death are known to be involved, such as AD (Fossati, Ghiso & Ros-
tagno, 2012b; Moreira, Carvalho, Zhu, Smith & Perry, 2010), Parkin-
son’s disease (Solesio, Prime et al., 2013; Solesio, Saez-Atienzar,
Jordan & Galindo, 2012), and Huntington’s disease (Solesio, Saez-
Atienzar, Jordan & Galindo, 2013).
Carbonic anhydrases (CA) are enzymes involved in the reversible
conversion of carbon dioxide and water into bicarbonate and pro-
tons. They are present in all the vertebrates, showing different intra-
cellular locations and regulating pH and ion transport. CA-VA and
CA-VB have a mitochondrial localization (Ghandour, Parkkila, Park-
kila, Waheed & Sly, 2000). CA-II, known as cytoplasmic, was also
recently shown by proteomic profiling to be increased in brain mito-
chondria in aging and neurodegeneration (Pollard, Shephard, Freed,
Liddell & Chakrabarti, 2016). CA inhibitors (CAIs) are used to treat a
variety of disorders including glaucoma, epilepsy, neuropsychiatric
disorders, and acute mountain sickness (Aggarwal, Kondeti &
McKenna, 2013; Fossati et al., 2016; Huang et al., 2010).
In this study, we examine multiple mitochondrial pathways of
amyloid toxicity in neuronal and cerebral endothelial cells (ECs), and
evaluate CAIs as active regulators of these processes. We analyze
changes in mitochondrial membrane potential, production of ATP,
emission of ROS (reactive oxygen species), mitochondrial and cyto-
plasmic calcium influx, as well as activation of caspase 9 and cell
death. While unveiling mechanistic insights into the deleterious mito-
chondrial actions of amyloid, we propose and test a novel therapeu-
tic approach for preventing these deleterious events. We analyze
the role of the CAI methazolamide (MTZ) and, for the first time, its
analog acetazolamide (ATZ), on specific Ab-mediated pathways of
mitochondrial dysfunction and apoptotic cell death, in both neuronal
cell lines and microvascular ECs, challenged, respectively, with Ab42
and the vasculotropic Ab40-Q22 (Fossati, Ghiso & Rostagno, 2012a).
Importantly, we include the analysis of mitochondrial toxicity in
cerebral endothelial cells. The deposition of amyloid (predominantly
Ab40) around cerebral vessels and microvessels, known as cerebral
amyloid angiopathy (CAA), is today recognized as an integral part of
the disease. In addition to the well-known neurodegenerative pathol-
ogy caused by the parenchymal deposition of Ab (mainly in its 42
amino acids form), CAA is known to cause vascular damage, micro-
and macro- hemorrhage, apoptosis, and dysfunction of the entire
neurovascular unit. These neurovascular effects further exacerbate
the pathology and progression of the disease (Revesz et al., 2009;
Zlokovic, 2008). Mutations in the Ab peptide generate variants such
as the Ab40-Q22 mutant, which are associated with CAA, hemor-
rhagic stroke, and early-onset dementia in AD familiar forms, induce
aggressive endothelial cell damage, and can represent useful tools to
study amyloid-mediated vascular pathology (Fossati et al., 2010).
MTZ was first selected from a drug library for its ability to inhibit
cytochrome C (CytC) release from isolated mitochondria, showing
beneficial effects in models of Huntington’s disease (Wang et al.,
2008) and ischemia-reperfusion injury (Wang et al., 2009). Albeit
pointing to a mitochondrial effect of MTZ, the mechanisms of action
were not fully clarified. MTZ prevented cell death and CytC release
in cellular and mouse models of Ab-induced neurodegeneration (Fos-
sati et al., 2016). This is the first study expanding the analysis to
other members of the CAIs family and deeply analyzing the mito-
chondrial mechanism of action of these drugs. Here, we thoroughly
examined the effects of two different FDA-approved and clinically
used members of the CAI family (MTZ and ATZ) on Ab-mediated
mitochondrial damage, and we tested for the first time if the protec-
tive effect induced by MTZ on CytC release, the resulting caspase-9
activation, and apoptosis, were also exerted by an analog CAI, ATZ.
The FDA has approved MTZ and ATZ for use in glaucoma decades
ago. CAIs are also currently approved for the prevention of acute
mountain sickness and related cerebral edema and as diuretics. Fur-
thermore, ATZ is used in the treatment for idiopathic intracranial
hypertension and normal pressure hydrocephalus (Alperin et al.,
2014). Their use in these neurological disorders as well as in epilepsy
(Aggarwal et al., 2013) confirms the ability of these drugs to reach
the brain at effective concentrations. Due to the long-term use of
MTZ and ATZ in chronic conditions, the efficacy and the safety of
their systemic administration have been widely assessed (Wright,
Brearey & Imray, 2008), making clinical trials for CAIs in AD a con-
crete possibility. Our novel findings on the mitochondrial effects of
MTZ and ATZ against neuronal and vascular amyloid toxicity justify
the selection of these drugs as a therapeutic strategy for AD and
CAA.
2 | RESULTS
2.1 | Ab treatment elicits mitochondrial membrane
depolarization and increases mitochondrial H2O2
production. CAIs counteract both effects
First, to determine the concentrations of MTZ and ATZ effective to
decrease the apoptotic effect of the Ab peptides in both cell lines,
we conducted a dose–response experiment measuring DNA frag-
mentation (Figure 1), which showed that ATZ is about 10-fold more
effective than MTZ at inhibiting apoptosis in both cell types. After-
ward, to clarify the molecular mechanisms responsible for the mito-
chondrial effects of Ab and to determine whether CAIs exert a
protective effect on these processes, we analyzed the main path-
ways responsible for maintaining mitochondrial function. Preserva-
tion of mitochondrial membrane potential (DΨ) is an essential
element for cell physiology, survival, and energetic function. Indeed,
mitochondrial membrane depolarization is known to precede and
facilitate apoptotic cell death. We studied the effects of Ab42 and
Ab40-Q22 on mitochondrial membrane potential in neuronal cells
(SH-SY5Y) and ECs, respectively. Membrane potential was measured
using TMRM fluorescent probe. Our data clearly showed that chal-
lenge with aggregated (oligomeric) forms of the Ab peptides induced
a depolarizing effect on the mitochondrial membrane of neuronal
cells and ECs, after only 45 min of treatment (Figure 2a). This effect
was especially dramatic in the case of microvascular ECs, where DΨ
was reduced more than 60% by Ab. It is interesting that the
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magnitude of the membrane depolarization induced by Ab fibrils and
monomers was significantly lower, compared to the depolarization
induced by the oligomeric forms. The scrambled Ab42 peptide, used
as a negative control, did not exert any effect on mitochondrial DΨ
(Figure 2a). On the other hand, addition of 10 lM of FCCP to com-
pletely depolarize mitochondria resulted in loss of fluorescent signal
in both cell lines (Supporting Information, Figure S1), confirming that
in our experimental conditions, TMRM fluorescence decrease
reflects the degree of mitochondrial depolarization.
Both MTZ and ATZ were able to rescue DΨ to values similar to
those observed in control. 100 lM was used as starting point for
MTZ, due to our data indicating an effect of this or higher doses
on preventing cell death [(Fossati, Todd, Sotolongo, Ghiso & Ros-
tagno, 2013; Fossati et al., 2016) and Figure 1]. ATZ, used for the
first time in this study, was able to prevent the loss of DΨ and to
maintain the potential at the level of control cells at a significantly
lower concentration (10 lM). To demonstrate that this effect was
specifically due to the inhibition of CAs by MTZ and ATZ, we used
N-methyl acetazolamide (100 lM), a structural analog of ATZ
unable to inhibit CAs. Treatment of SH-SY5Y cells with the analog
exerted no effect on DΨ, either under control conditions or in the
presence of Ab.
Increased production of mitochondrial H2O2 is a classical signal
of mitochondrial dysfunction and an essential mediator of cell death
(Singh, Sharma & Singh, 2007). H2O2 is a membrane permeable sec-
ond messenger, as well as a potent precursor of other ROS genera-
tion (Turrens, 2003). H2O2 production is also tightly regulated by
DΨ. We measured the levels of H2O2 produced by isolated mito-
chondria purified after neuronal and ECs treatment with Ab, in the
presence or absence of the CAIs. Ab induced a significant increase
in the amount of H2O2 generated by isolated mitochondria (three-
fold increase in neuronal cells and about 1.5-fold increase in ECs), as
estimated from Amplex Red fluorescence (Figure 3a). Emission of
H2O2 was inhibited in the presence of ATZ or MTZ. While in neu-
ronal cells both drugs completely reverted the effect of Ab, ATZ,
albeit used at lower concentrations than MTZ, had a more significant
effect on ECs (Figure 3a).
2.2 | Modulation of mitochondrial and cytoplasmic
calcium levels
Fluctuations in mitochondrial-free Ca2+ are usually linked to mito-
chondrial dysfunction and cell death and they have been previously
described in specific cell types challenged with amyloid peptides.
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F IGURE 1 Dose–response curve of Ab
and CAIs. Apoptotic cell death was
measured by Cell Death ELISAplus in
neuronal cells (a, b) and microvascular ECs
(c, d). Increasing concentrations of CAIs
and 10 lM of Ab42 (a, b) or 50 lM of
Ab40-Q22 (c, d) were added to the cell
cultures. Data in histograms are
mean  SEM of at least three independent
experiments
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Using specialized fluorescent dyes (Rhod-2/mitochondrial Ca2+ and
Fluo-4/cytoplasmic Ca2+), we measured the levels of mitochondrial
and cytoplasmic-free Ca2+ (Figure 4). Due to their charge, rho-
damine-based calcium probes are known to be preferentially local-
ized in mitochondria (Smithen et al., 2013). This fact was confirmed
under our experimental conditions, as shown in Supporting Informa-
tion, Figure S2a, insert.
Surprisingly, we found that an acute treatment (45 min) with
pre-aggregated oligomeric Ab peptides decreased mitochondrial-free
calcium levels in both cell types (Figure 4a–b). It is interesting that
when we analyzed cytoplasmic Ca2+, we detected a similar effect to
that observed in the mitochondria, although the decrease was not
significant in ECs (Figure 4c–d). CAIs, given together with the pep-
tide for 45 min, did not affect the decreased levels of mitochondrial
*
Sc
ram
ble
d A
β4
2
Ct
rl
Aβ
42
 ol
igo
me
rs
Aβ
42
 fib
rils
Aβ
42
 m
on
om
ers
***
*
***
(a)
******
Ct
rl
Q2
2 o
lig
om
ers
Q2
2 f
ibr
ils
Q2
2 m
on
om
ers
Sc
ram
ble
d A
β4
2
*
***
10 μM 50 μM
(b)
***
Aβ
42
 10
 μM
 + 
AT
Z 1
00
 μM
Aβ
42
 10
 μM
 + 
AT
Z 1
0 μ
M
Aβ
42
 10
 μM
 + 
MT
Z 3
00
 μM
Aβ
42
 10
 μM
 + 
MT
Z 1
00
 μMCt
rl
Aβ
42
 10
 μM
**
***
***
*
Q2
2 5
0 μ
M 
+ M
TZ
 30
0 μ
M
Q2
2 5
0 μ
M 
+ A
TZ
 10
 μM
Q2
2 5
0 μ
M 
+ A
TZ
 10
0 μ
M
Q2
2 5
0 μ
M 
+ M
TZ
 10
0 μ
M
Q2
2 5
0 μ
MCt
rl
***
***
**
**
***
0
20
40
60
80
100
120
Aβ
42
 10
 μM
 + 
AT
Z A
na
log
AT
Z A
na
logCt
rl
TM
R
M
 fl
uo
re
sc
en
ce
 (%
)
0
20
40
60
80
100
120
TM
R
M
 fl
uo
re
sc
en
ce
 (%
)
0
20
40
60
80
100
120
TM
R
M
 fl
uo
re
sc
en
ce
 (%
)
0
20
40
60
80
100
120
TM
R
M
 fl
uo
re
sc
en
ce
 (%
)
0
20
40
60
80
100
120
TM
R
M
 fl
uo
re
sc
en
ce
 (%
)
Aβ
42
 10
 μM
***
***
F IGURE 2 Mitochondrial membrane depolarization induced by Ab oligomers is prevented by CAIs. Graphs showing mitochondrial
membrane potential (DΨ) measured by TMRM in SH-SY5Y neuronal cells (left) and microvascular ECs (right). (a) The monomeric and fibrillar
forms of the peptides induced a much lower mitochondrial membrane depolarization. It is interesting that the scrambled form of the peptide
did not exert any effect on DΨ in any of the cell lines. Ab42, on its different aggregation states, was always added at 10 lM, while the final
concentration of Q22 was 50 lM. (b) DΨ in the neuronal cells (left panel) is reduced to about 65% of control cells. The reduction is completely
prevented by MTZ and ATZ. In ECs cells (central panel), DΨ is reduced to 35% of the control levels by Ab, and reverted to above 80%, after
treatment with the peptide in the presence of CAIs. N-methyl acetazolamide (100 lM), a structural analog of ATZ unable to inhibit CAs,
showed no effect on DΨ either under control conditions or in the presence of Ab, in SH-SY5Y cells (right panel). Data in histograms are
mean  SEM of, at least, three independent experiments
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and cytoplasmic Ca2+ in neuronal cells, while in ECs, the highest
doses of MTZ and ATZ were able to counteract the effect exerted
by the peptide (Figure 4b, d).
To exclude experimental artifacts, we subjected the cells to dif-
ferent loading and washing times, which consistently resulted in
decreased levels of free calcium in both mitochondrial and
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F IGURE 3 Increase in mitochondrial
H2O2 production in response to Ab and its
inhibition in the presence of CAIs. Effect
of Ab on cellular production. (a) Data show
the relative amount of H2O2 produced by
isolated mitochondria expressed as FOC of
the control (Ctrl), as measured by Amplex
Red in SH-SY5Y cells (left) and in ECs
(right). H2O2 production significantly
increases when cells are treated with Ab42
10 lM or Q22 50 lM. The release of
H2O2 is prevented when CAIs are added
together with Ab. Both the level of H2O2
production and the efficiency of its
inhibition are more extreme in neuronal
cells, compared to ECs. General oxidative
stress within the cell, measured by
CellROX (b) and DCFDA (c) reagents in
neuronal cells (left) and ECs (right), is not
significantly affected by Ab challenge. The
addition of CAIs does not significantly
change the amount of intracellular ROS
present in any of the two cell types. Data
in histograms are mean  SEM of at least
three independent experiments
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cytoplasmic compartments after Ab challenge. Pretreatment with the
drugs for 3 hr did not produce any significant difference in Ca2+
influx, compared to simultaneous addition of peptides and CAIs
(Figure 4e). Rhod-2 has some limitations, mainly related to the fact
that it responds to fluctuations in Ca2+ concentration not by chang-
ing the emission and/or the excitation spectrums, but by variations
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F IGURE 4 Effect of Ab on calcium
homeostasis and differential impact of
CAIs. (a, b) Graphs show mitochondrial
calcium accumulated in the presence of Ab
(respectively, Ab42 10 lM or Q22 50 lM)
with or without MTZ (100 or 300 lM) or
ATZ (10 or 100 lM) in (a) SH-SY5Y cells
and in (b) ECs. (c, d) Cytoplasmic calcium
concentration in the same cell types and
under the same treatments is represented.
(e) Pretreatment of the cells with the drugs
before challenge with Ab does not
significantly affect mitochondrial and
cytoplasmic calcium concentration. Data in
histograms in (a, b, c, d, and e) are
mean  SEM of at least three independent
experiments
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in the intensity of the fluorescence. In addition, uneven distribution
of the dye within mitochondria could also occur when using this
probe. However, rhodamine-based fluorescence probes have been
extensively used in the literature as a method to assay mitochondrial
calcium (Abramov & Duchen, 2003; Babcock, Herrington, Goodwin,
Park & Hille, 1997; Boitier, Rea & Duchen, 1999), and we conducted
all the experiments accurately and using the appropriate controls.
2.3 | Carbonic anhydrase inhibition does not affect
intracellular pH or ATP generation
CA catalyzes the interconversion of CO2 and H2O to HCO

3 and
protons, through a reversible reaction (Meldrum & Roughton, 1933).
For this reason, upon enzyme inhibition, the intracellular levels of
bicarbonate may vary. Because bicarbonate is one of the most
important components of the pH buffering system of the human
body, changes in its concentration may produce dramatic variations
in the intracellular pH. In our conditions, no changes in intracellular
pH were elicited by either the Ab peptides or the CAIs for the dura-
tion of the experiments, even if Ab was aggregated prior to treat-
ments (Figure 5a and b), showing that cellular pH changes do not
mediate the CAIs protective effects.
To examine a possible effect of CAIs on proton flux across the
inner mitochondrial membrane and energy production, we measured
cellular ATP levels in permeabilized cells, using a luciferin-luciferase
assay. Dissimilar results were obtained in SH-SY5Y and ECs. Treat-
ment of SH-SY5Y cells with Ab induced a modest decrease in ATP
levels (p = 0.05, Figure 5c). These levels remained unchanged upon
treatment with MTZ or ATZ in combination with the peptide. As a
control, treatment with ATP synthase inhibitor oligomycin induced a
sharp decrease (p < 0.0001). In contrast, treatment of ECs with the
Q22 peptide induced a 21.6% increase in steady-state ATP levels
(p = 0.001, Figure 5c). This increase was unaffected by cotreatment
with either MTZ or ATZ. It is interesting that oligomycin, similar to
Ab, also increased ATP luminescence in the ECs (p = 0.0002).
2.4 | Ab-induced apoptosis and caspase activation
are prevented by CAIs
Apoptotic cell death is a well-known contributor to neurovascular
degeneration in AD. CytC release from dysfunctional mitochondria
and the resulting caspase-9 activation are known to play key roles in
the apoptotic process. We have recently reported a protective effect
of MTZ against apoptotic cell death in models of Ab-induced toxicity
(Fossati et al., 2016). Here, we tested for the first time if the protec-
tive effect induced by MTZ on caspase activation and CytC release
was also exerted by the analog CAI ATZ.
We analyzed the effect of MTZ on amyloid-mediated mitochon-
drial cell death pathways, showing that Ab-induced CytC release
(Figure 6a and b), caspase-9 activation (Figure 6c and d), and DNA
fragmentation (Figure 1a–d) were inhibited by MTZ starting at
100 lM concentration, which confirmed our recent work (Fossati
et al., 2016). Importantly, ATZ was effective in preventing CytC
release and caspase-9 activation, as well as apoptosis, at concentra-
tions 10 times lower than MTZ, starting at concentrations ≤10 lM
(Figures 1a–d and 6). ATZ completely reverted Ab-induced caspase-9
activation (Figure 6).
3 | DISCUSSION
Mitochondrial dysfunction is an early and causal step in AD pathol-
ogy, tightly linked to neurodegeneration and promoting cognitive
impairment (Hirai et al., 2001; Swerdlow, Burns & Khan, 2014;
Swerdlow & Khan, 2009; Swerdlow et al., 2010). The apoptotic out-
come has been attributed to the pathological effects of Ab interme-
diate aggregation species (particularly oligomers and protofibrils) on
mitochondrial pathways (Fossati et al., 2010, 2012b). However, the
specific biochemical pathways leading to mitochondrial dysfunction
in the presence of amyloid, as well as the resulting activation of cell
death pathways in neurovascular cells, are still unclear.
Here, we revealed that CAs might be previously unrecognized
key targets in these processes. Our results clearly showed induction
of mitochondrial membrane depolarization and increased mitochon-
drial H2O2 production, in response to Ab-challenge, in both neuronal
and cerebral microvascular ECs. MTZ and ATZ, two different mem-
bers of the CAI family, were effective at inhibiting the mitochondrial
dysfunction pathways induced by Ab. Intriguingly, other mitochon-
drial parameters, such as ATP production and pH, were not equally
affected. Moreover, mitochondrial and cytoplasmic calcium flux did
not seem to be essential for the mechanism of action of the CAIs.
In the presence of Ab, mitochondrial membranes were strongly
depolarized and mitochondrial production of H2O2 was increased.
These data are concordant with previous reports, showing that the
Ab peptide affects the production of different types of ROS, includ-
ing H2O2 (Kaminsky & Kosenko, 2008). The essential role played by
mitochondrial H2O2 production in the activation of the apoptotic
pathway in our study is concordant with previous work showing that
increments in the generation of this molecule appear early after Ab-
challenge (Milton, 2004; Tabner et al., 2005). In our model, H2O2
production and mitochondrial membrane depolarization, which is also
a key process in AD pathogenesis (Moreira et al., 2010), appear as
primary inductors of Ab-mediated apoptotic cell death and as the
main targets of CAIs. Both parameters were clearly reverted when
CA was inhibited by MTZ and ATZ.
It is interesting that despite the increase in H2O2 produced by
mitochondria isolated after cell treatment with Ab (Figure 3a), other
intracellular ROS measured in whole cells were not increased in
response to Ab in our model (Figure 3b and c). The differences
between the effects exerted by the Ab peptides on H2O2 release by
isolated mitochondria and on other types of ROS measured in whole
cells can be explained by the ability of H2O2 to rapidly cross mem-
branes and be released extracellularly. In line with this hypothesis,
while the use of Amplex Red allows to study the amount of H2O2
released into solution by mitochondria after cell lysis, CellROX and
DCFDA only quantify the amount of ROS in the intracellular space,
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where likely H2O2 is not continually present, due to its ability to
cross membranes. The fact that H2O2 is highly unstable and that it
reacts with lipids and proteins, inducing peroxidation, is also in line
with the proposed hypothesis.
To determine whether CAIs affect energy production or proton
availability after Ab challenge, we measured ATP levels in the pres-
ence or absence of CAIs. It is interesting that despite cell type differ-
ences likely due to different coupling properties, MTZ or ATZ
treatment did not affect the steady state of ATP, either in control
conditions or in cells treated with Ab. These results suggest that
energy production and proton flux are not involved in the CAIs’
mechanism of action, which seems primarily driven by the preven-
tion of mitochondrial DΨ changes and by the reduction in mitochon-
drial H2O2 release. Thus, the protective effects of CAIs against
amyloid peptides are not due to an increase in mitochondrial respira-
tion. It is interesting that the amyloid peptides alone exerted differ-
ential effects on SH-SY5Y and ECs, inducing a slight decrease in
ATP levels in neuronal cells and a substantial increase in cerebral
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F IGURE 5 Intracellular pH and ATP
production are not affected by CAIs.
Measurement of the intracellular pH after
3 hr of treatment with the pre-aggregated
peptide is shown in (a) for SH-SY5Y and
for ECs. The same pH measurement after
16 hr of treatment with Ab without pre-
aggregation is represented in (b) (Ab42
10 lM or Q22 50 lM). Cellular pH is not
significantly affected by Ab and CAIs (MTZ
100 or 300 lM and ATZ 10 or 100 lM).
(c) Bar histograms showing ATP production
in response to Ab peptides or to peptides
in the presence of CAIs for SH-SY5Y and
ECs cell cultures. ATP production is
measured by a luminometric assay (CellGlo,
Promega) and is represented as A.U. Data
in histograms are mean  SEM of, at least,
three independent experiments
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ECs. A possible explanation is that these cell types handle mitochon-
drial dysfunction by differentially resorting to aerobic glycolysis
(Newington et al., 2011). In fact, we can presume fundamentally dif-
ferent glycolytic metabolism for neuronal cells (such as SHSY-5Y)
and ECs. This may explain the different effects induced by the ATP
synthase inhibitor oligomycin in our experiments and strengthens
our conclusion that the protective mechanisms of CAIs are indepen-
dent of ATP production.
Maintaining the proper mitochondrial calcium concentration is
imperative for cell survival. In fact, mitochondria, jointly with the ER,
are the two main organelles in charge of keeping calcium cell home-
ostasis. However, while in the ER the levels of free calcium are kept
within the physiological range by a group of proteins called calse-
questrins (MacLennan & Wong, 1971), mitochondria lack any specific
protein to exert this action, and the mechanism governing this pro-
cess is still unclear.
Previous work showed that Ca2+ homeostasis is dysregulated in
cellular models of AD, as well as in human AD brains (Berridge,
Bootman & Lipp, 1998; Celsi et al., 2009; Garwood et al., 2013).
Surprisingly, our data showed decreased levels of free calcium, both
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F IGURE 6 Protective effect of CAIs on Ab-induced CytC release and caspase-9 activation. ATZ prevents CytC release in response to Ab in
(a) SH-SY5Y and (b) ECs cells. Images were acquired by confocal microscopy after immunocytochemistry. Chain-like mitochondrial Cyt C
(arrowheads) in healthy cells or diffused cytoplasmic CytC (arrows) in cells undergoing apoptosis is stained in green. Nuclei are marked in blue
with Hoechst 33342. Nuclear condensation indicates apoptosis. The protective effect of MTZ and ATZ on caspase-9 activation is shown in (c)
for SH-SY5Y and (d) for ECs cell cultures. Data in histograms are mean  SEM of at least three independent experiments
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in mitochondria and in cytoplasm, after the addition of the Ab pep-
tides. A previous study showed decreased levels of mitochondrial
Ca2+ under pathological conditions (Granatiero et al., 2015). Discor-
dant results have been reported regarding the effects of Ab on cellu-
lar and mitochondrial calcium, with studies showing data both
consistent and contradictory with our findings (Abramov, Canevari &
Duchen, 2003, 2004).
The observed effect on mitochondrial and cytoplasmic calcium
concentration was partially rescued by the highest concentrations of
MTZ and ATZ in microvascular ECs, reaching values similar to those
found under control conditions, while no modulation by CAIs was
observed in neuronal cells. This is key evidence that mitochondrial
CAIs effects on Ab-induced toxicity are independent of calcium
uptake in both mitochondria and cytoplasm, as even in conditions in
which CAIs do not affect mitochondrial and cytoplasmic Ca2+ flux
(neuronal cells), CAIs are able to inhibit loss of DΨ and production of
H2O2, as well as caspase activation and cell death. In the absence of
an obvious effect of CAIs on mitochondrial Ca2+ levels, we con-
cluded that the observed effects are independent of Ca2+ homeosta-
sis. Thus, rather than examining pathways in which fluctuating levels
of mitochondrial Ca2+ has been shown, as the opening of the mito-
chondrial permeability transition pore or the ER-mitochondria inter-
actions, we opted to focus our studies on other mitochondrial
parameters affected by CAIs. One of the main consequences of the
over dosage of CAIs in humans is the imbalance in the serum elec-
trolyte levels and the resultant change in blood pH (Crandall, Bidani
& Forster, 1977). Small increases in the pH of the solutions where
MTZ and ATZ are dissolved are also linked to increases in their solu-
bility (Jiang et al., 2013) and may induce changes in the bioavailable
concentration of the CAIs, introducing more complexity in our study.
Therefore, we monitored possible changes in the intracellular pH
upon cell treatment with the CAIs, which could affect Ab-induced
toxicity. No significant changes in the pH were found (Figure 5b and
c). This allowed us to exclude that the protective effects of CAIs
were secondary to pH modulation.
As expected, CytC release and caspase-9 activation were
induced by Ab challenge in both neuronal and microvascular ECs.
DNA fragmentation, indicating apoptotic cell death, was also
increased by Ab in both cell types. This is the first study showing
that two different CAIs were able to counteract the detrimental
effects of Ab on mitochondrial dysfunction and apoptotic cell death
and to analyze their mitochondrial mechanisms of action. While pre-
vious findings in neurodegenerative diseases have proposed a role of
MTZ in the prevention of mitochondrial dysfunction and CytC
release (Fossati et al., 2013, 2016; Wang et al., 2008, 2009), these
studies did not explore the potential protective effects of other
CAIs, and did not show that the effects were specifically due to CA
inhibition. We hypothesized that the prevention of Ab-mediated
mitochondrial dysfunction may be due to a direct effect on mito-
chondrial and/or cellular CAs, as shown by the lack of effect of an
inactive ATZ analog. Albeit none of the CAIs available today are fully
selective for one of the enzymes, both MTZ and ATZ have high
activity on mitochondrial CA (CA-VA and -VB) (Supuran, 2008).
In our models, CAIs prevent Ab-induced apoptosis by inhibiting
loss of DΨ and production of H2O2, as well as CytC release from the
mitochondria. A possible mechanism responsible for the prevention
of mitochondrial depolarization and H2O2 production is that pharma-
cological inhibition of mitochondrial CAs slows down the production
of HCO3 , limiting Krebs cycle and electron transport chain, and thus
reducing the production of H2O2 and subsequent oxidative stress.
This mechanism is also proposed by Shah’s group, who showed that
inhibition of CAs rescued high-glucose induced mitochondrial dys-
function, ROS production, and pericyte loss in diabetic mice (Price,
Eranki, Banks, Ercal & Shah, 2012; Shah, Morofuji, Banks & Price,
2013). The known effects of CAIs on specific ion channels, aquapor-
ins (Kamegawa, Hiroaki, Tani & Fujiyoshi, 2016), or other receptors
which interact with Ab on mitochondrial or cell membranes may also
be mechanisms responsible for the amelioration of Ab-induced mito-
chondrial dysfunction (Aggarwal et al., 2013). More studies will be
needed to further clarify these molecular mechanisms.
Our results suggest a new and critical role for CA inhibition in
the regulation of Ab-induced neuronal and microvascular toxicity,
both essential underlying processes of AD etiopathology, through an
effect of the CAIs on specific pathways of mitochondrial dysfunc-
tion. Importantly, the mitochondrial effects are exerted not only by
MTZ, but also by another member of the CAIs family, ATZ, which is
effective at even lower concentrations. These concentrations are in
the range of those achieved clinically in the brain. Although clinical
trials will be required to ultimately demonstrate effects in AD or
other dementias, the translatability of our findings will be increased
if the protective effects of CAIs are demonstrated in transgenic ani-
mal models of amyloidosis. We have previously shown reduced cas-
pase activation and neuronal death after Ab intracerebral injection in
mice treated with a concentration of MTZ of 10 mg/kg, that after
allometric scaling is significantly under the maximum recommended
dose for human adults (Fossati et al., 2016). Promising studies in
transgenic mouse models of amyloidosis are currently ongoing in our
laboratory. The physiological relevance of this approach is further
highlighted by recent proteomic studies showing increased CAII in
the mitochondria in aging and neurodegeneration (Pollard et al.,
2016), as well as by our group’s recent findings demonstrating the
presence of multiple CA enzymes in amyloid plaques within the AD
human brain (Drummond et al., 2017).
This study, clarifying for the first time the mitochondrial molecu-
lar mechanisms of MTZ and ATZ protection against Ab toxicity,
paves the way for future clinical trials aimed to repurpose these and
other FDA-approved CAIs against AD and dementia.
4 | EXPERIMENTAL PROCEDURES
4.1 | Reagents
Dulbecco’s modified Eagle medium:F12 1:1 (DMEM:F12), penicillin-
streptomycin, and fetal bovine serum (FBS) were purchased from
Gibco-Invitrogen (Carlsbad, California); anti-active caspase-3 anti-
body from Santa Cruz Biotechnology (Dallas, Texas); protease
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inhibitors and cell death detection ELISA plus kit from Roche (Basel,
Switzerland); endothelial cell growth medium (EBM-2) and growth
supplements from Lonza (Basel, Switzerland); MTZ, ATZ, 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP), dimethyl sulfoxide (DMSO), Triton X-
100 solution, bovine serum albumin (BSA), sucrose, mannitol and
Tris-HCl, phenylmethylsulfonyl fluoride (PMSF), oligomycin, and p-tri-
fluoromethoxyphenylhydrazone (FCCP) from Sigma-Aldrich (St. Louis,
Missouri); caspase-Glo 9 assay and Cell Titer-Glo assay from Pro-
mega (Madison, Wisconsin); Amplex Red hydrogen peroxide/peroxi-
dase assay kit and CM-H2DCFDA (general oxidative stress indicator)
from Thermo Fisher (Waltham, Massachusetts); paraformaldehyde
20% (PFA) from Electron Microscopy Sciences, (Hatfield, Pennsylva-
nia); Rhod-2 AM, Fluo-4 AM, tetramethylrhodamine methyl ester
(TMRM), Hank’s balanced salt solution (HBSS), MitoTracker Red,
CellROX deep red reagent, pHrodo green AM and Hoechst 333258
from Thermo Fisher (Waltham, Massachusetts); and Alexa Fluor 488
antibody from Abcam (Cambridge, UK).
4.2 | Cell cultures
The neuroblastoma SH-SY5Y cell line was purchased from the Amer-
ican Type Culture Collection (ATCC, Manassas, Virginia) and grown
as using DMEM:F12 medium supplemented with 20 units/ml peni-
cillin-streptomycin and 15% (v/v) FBS. Immortalized human brain
microvascular endothelial hCMEC/D3 cells (ECs) were obtained from
Babette Weksler and grown in complete EBM-2 medium, containing
all the growth supplements (Hydrocortisone, hFGF-B, VEGF, R3-
IGF-1, ascorbic acid, hEGF, GA-1000, and heparin), 20 units/mL
penicillin-streptomycin, and 5% FBS. Both cell lines were grown in a
humidified cell culture incubator, under a 5% CO2 atmosphere and
at 37°C.
4.3 | Drug preparation
MTZ and ATZ were both dissolved in DMSO to stock solutions of
300 mM and kept at 20°C until the day of the experiment. The
CAIs were thawed at room temperature and then dissolved in the
specific medium used in each experiment to the final concentrations,
(30 to 300 lM in the case of MTZ and 1 to 100 lM for ATZ).
4.4 | Ab peptides
Synthetic Ab42 was synthesized using N-tert-butyloxycarbonyl
chemistry by James I. Elliott at Yale University and purified by
reverse-phase high-performance liquid chromatography on a Vydac
C4 column (Western Analytical, Murrieta, California, US). Ab40-Q22
(the Dutch genetic variant, containing the E22Q substitution) was
synthetized by Peptide 2.0 Inc. (Chantilly, Virginia, USA) and purified
by HPLC/MS. Purity was >95%. Scrambled Ab42 was purchased
from Bachem (Torrance, California, USA). Ab homologs were dis-
solved to 1 mM in HFIP, incubated overnight to break down preex-
isting b-sheet structures (Fossati et al., 2010), and lyophilized.
Peptides were subsequently dissolved in DMSO to a 10 mM
concentration, followed by the addition of deionized water to 1 mM
concentration and by further dilution into the medium in which the
experiments were run, to a final concentration of 10 lM in the case
of Ab42 and to 50 lM in the case of the Ab40-Q22. Peptide treat-
ments were performed in EBM-2 supplemented with FBS 1% and in
DMEM:F12 with no FBS or 1% FBS, for ECs and SH-SY5Y cells,
respectively.
4.5 | Peptide preparation
In brief, HFIP-pretreated and lyophilized peptides were resuspended
in DMSO to a 10 mM concentration, immediately prior to use. After
that, peptides were directly used in the case of the monomeric
preparations and added to the cells at the specified concentrations.
Peptide pre-aggregation to obtain oligomeric and fibrillar prepara-
tions was performed following the protocol published by Dahlgren
et al. (2002). Aggregates were then added to the cells at the desired
concentrations, alone or in cotreatment with the different CAIs.
Monomeric, oligomeric, or fibrillary state of the preparations was
tested by EM as we previously published (Fossati et al., 2010).
4.6 | Caspase-9 activation
Cells were plated at a confluence of 10,000 cells per well in 96-well
luminescence microtiter microplates (Thermo Fisher, Waltham, Mas-
sachusetts, US). The day after, cells were treated with the peptides
and/or CAIs for the experimental times. After that, caspase-Glo 9
assay (Promega, Madison, Wisconsin, USA) was performed, following
the protocol provided from the manufacturer. Luminescence was
measured using a FlexStation 3 Multi-Mode Microplate Reader
(Molecular Devices, Sunnyvale California, USA).
4.7 | Amplex Red
Cells were plated on 6-well plates and treated with the peptides
and/or CAIs for the experimental times. Plates were centrifuged for
10 min at 200 RCF and washed twice with PBS 19. Afterward, to
isolate the mitochondria, 500 ll of homogenization buffer (75 mM
sucrose, 225 mM mannitol, 5 mM Tris-HCl pH = 7.4, 1 mM PMSF,
and protease inhibitor cocktail) was added. Cells were scraped in
this buffer, collected in glass tubes, and grinded exactly 80 times
with a pellet pestle, keeping everything always on ice. Cells were
then centrifuged at 800 RCF for 5 min at 4°C. The supernatant was
collected and centrifuged again at 800 RCF for 5 min at 4°C. The
supernatant was again collected and centrifuged at 11700 RCF for
another 5 min at 4°C. After this, the supernatant was discarded,
and the pellet was resuspended in 100 ll of homogenization buffer.
The samples were centrifuged again at 11700 RCF for 10 min at
4°C, the supernatant was discarded, and the pellets (mitochondrial
fractions) were resuspended on 50 ll of homogenization buffer. A
protein concentration assay on mitochondrial protein was performed
using the Pierce BCA Protein Assay Kit (Thermo Fisher, Waltham,
Massachusetts, USA) and following the instructions provided by the
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manufacturer. After that, mitochondrial fractions containing equal
amounts of mitochondrial proteins were placed on 96-well absor-
bance microtiter microplates (Thermo Fisher, Waltham, Mas-
sachusetts, USA), and the Amplex Red assay was run, following the
instructions provided by the manufacturer. Absorbance was
measured by using a FlexStation (Molecular Devices, Sunnyvale
California, USA).
4.8 | Immunocytochemical evaluation of
Cytochrome C release
SH-SY5Y and microvascular ECs cells were plated on 15-mm optical
borosilicate poly-L-lysine-coated sterile glass covers (Thermo Fisher,
Waltham, Massachusetts, USA) at a 70% confluence. After 24 hr,
cells were treated with the peptides in the presence or absence of
MTZ or ATZ for 16 hr. Cells were then washed with PBS, fixed with
4% paraformaldehyde (10 min, RT), washed again, and blocked with
20 mg/ml BSA in PBS containing 0.3% Triton X-100 (PBST). Slides
were further incubated with mouse monoclonal anti-CytC antibody
(BD Biosciences; 1:200 in PBST containing 5 mg/ml BSA; 2 hr, RT)
followed by Alexa Fluor 488-conjugated anti-mouse IgG (Thermo
Fisher, Waltham, Massachusetts, USA) 1:200 in PBST with 5 mg/ml
BSA for 1 hr at RT, as previously described fluorescence signals
were visualized in a Zeiss LSM 510 laser scanning confocal/Confo-
cor2 microscope using a 409 DIC oil immersion objective and LSM
510 software; acquired images were processed and analyzed using
ImageJ (National Institute of Health).
4.9 | Mitochondrial and cytoplasmic calcium assay
This assay was performed as previously published in F. In brief, cells
were plated on 25-mm optical borosilicate poly-L-lysine-coated ster-
ile glass covers, (Thermo Fisher, Waltham, Massachusetts, USA) at a
70% confluence. 24 hr later, cells were loaded with 5 lM Rhod-2
AM or 2.5 lM Fluo-4 AM on HBSS for 45 min. Then, cells were
washed twice with HBSS and incubated for an additional 15 min on
fresh HBSS, without Rhod-2 AM or Fluo-4 AM. After that, HBSS
was replaced again by fresh HBSS, glasses were mounted on micro-
scopy chambers, and experiments were conducted, after adding the
pre-aggregated peptides and/or the CAIs. Cells were mounted on
Sykes-Moore chambers (BellCo, Vineland, New Jersey, USA) and
imaged every 15 s for 45 min, at a 209 magnification, using a Nikon
fluorescent microscope (Chiyoda, Tokyo, Japan). The calcium iono-
phore ionomycin (5 lM) was added at the end of the experiments to
test whether the cells were still functional and able to maintain cal-
cium gradient between cytoplasm and extracellular media after
45 min of experiment and to estimate the degree of maximal fluo-
rescence (Supporting Information, Figure S2). Images were analyzed
using NIS-Elements and ImageJ software. Specifically, at least 10
ROIs per field were marked in mitochondrial (Rhod-2) and cytoplas-
mic areas (Fuor-4) in all the images, and a time measurement of the
intensity in both fluorophores was conducted. The fluorescence for
each time point was normalized to the fluorescence value measured
at time = 0 s. and expressed as a percentage of this initial fluores-
cence. Results of typical experiment are shown in Supporting Infor-
mation, Figure S2. Please note that under these experimental
conditions, a spontaneous moderate increase on Fluo-2 and Rhod-2
fluorescence was observed, even under control conditions (Support-
ing Information, Figure S2a–b). Due to the time frame of these
experiments, the peptide was pre-aggregated as described above to
obtain oligomers before being added to the cells.
4.10 | TMRM assay
TMRM assay was performed using the probe in nonquenching mode
conditions, as previously described in (Abramov, Fraley, et al., 2007).
Cells were plated on 25-mm optical borosilicate poly-L-lysine-coated
sterile glass covers (Thermo Fisher, Waltham, Massachusetts, USA)
at a 70% confluence. The day after, cells were washed twice with
HBSS and charged with 60 nM TMRM on HBSS. Cells were then
incubated for 20 min in the incubator at 37°C and washed again
with HBSS. After that, the medium was replaced by HBSS containing
15 nM of TMRM, to maintain the equilibrium distribution of the flu-
orophore. As shown in Supporting Information, Figure S1 under our
experimental conditions, addition of FCCP leads to an abrupt drop in
fluorescence. This confirms that TMRM fluorescence directly reflects
the values of mitochondrial membrane potential and no appreciable
quenching of TMRM fluorescence occurred. Cells were then
mounted on Sykes-Moore chambers (BellCo, Vineland, New Jersey,
USA) and treated with the different CAIs and/or peptides. An image
was taken at minute 0 and at minute 45, after adding the CAIs and/
or peptides with different aggregation states.
4.11 | pH measurement
Cells were plated on 96-well fluorescence microtiter microplates
(Thermo Fisher Scientific). The day after, cells were treated with the
different CAIs and/or peptides. After treatment, intracellular pH mea-
surement was performed using the pHrodo red AM kit (Thermo Fisher
Scientific), following the indications provided by the manufacturer.
4.12 | ATP measurement
Steady-state levels of ATP were estimated using the Cell Titer-Glo,
according to manufacturer’s instructions. In brief, 5 9 103 cells per
well of both ECs and SH-SY5Y cells were plated on 96-well plates.
The day after, cells were treated with either 10 lM Q22 or 50 lM
Ab42 peptides, respectively. Peptides were added alone or in combi-
nation with increasing concentrations of MTZ (100 and 300 lM) or
ATZ (10 and 100 lM). Controls were treated with either DMSO or
5 lM oligomycin. After 3 hr of treatment, the plates containing the
cells were equilibrated to room temperature for 30 min prior to
addition of the luciferin/luciferase/cell lysis mixture. Absolute lumi-
nescence from quadruplicate experiments was recorded using a
SpectraMax plate reader (Molecular Devices, Sunnyvale California,
USA).
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4.13 | Statistical analysis
Statistical significance of differences between groups was deter-
mined by Student’s t test or two-tailed Student’s t test. Moreover, in
experiments containing more than two groups, the statistical signifi-
cance was determined by ANOVA with turkey post-hoc test. For the
statistical analysis and the graphical representation, we used Origins
Lab (Northampton, Massachusetts, USA) software and GraphPad
Prism (GraphPad, La Jolla, CA). Values of p ≤ 0.05 were considered
significant. (* p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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